Fig. 2

Effects of curcumin and resveratrol on the cell viability and cell cycle analysis of CT26 cells. (a) Cells were treated with curcumin (c), resveratrol (R), and the combined (C20 + R25, C20 + R50 μM) at the indicated concentration for 24 h. Cell viability was detected through WST1 assay. The results were represented the mean ± S.D. of three independent experiments. DMSO and EtOH served as the solvent control. (b) The cell viability of CT26 cells treated with curcumin. The IC50 of curcumin was 26.76 ± 1.06 μM. (c) The cell viability of CT26 cells treated with resveratrol. The IC50 of resveratrol was 88.76 ± 1.07 μM. d. Curcumin and resveratrol combination showed synergistically anti-tumor efficacy. (e) CT26 cells were treated with curcumin (20 μM) and resveratrol (25 μM) for 24 h and the cell cycle was analyzed by PI staining and flow cytometry. (f) Cyclin D1 and (g) Cyclin A expressions of CT26 cells treated by the indicated curcumin and resveratrol treatments with or w/o the 42 °C water bath (42w) and 42 °C mEHT (42 m) were analyzed by the western blot. Treating groups: DMSO + EtOH (DE, vehicle control), curcumin 20 μM (C20), resveratrol 25 μM (R25), curcumin 20 μM combined resveratrol 25 μM (C20R25). *P < 0.05, **P < 0.01 as compared to the control group. The full-length blots were presented in Supplementary Figure 2